“`html
food and Drug Administration (FDA) officials are urging drug developers to conduct long-term studies on the use of CAR-T cell therapy for autoimmune diseases, citing concerns about potential long-term effects such as cancer and fertility issues.
FDA Calls for Extended Monitoring of CAR-T Therapy in Autoimmune Disease Treatment
The recommendations, outlined in an op-ed published in the Annals of Internal Medicine on February 2, 2026, come from Vinay prasad, head of the FDA’s Center for Biologics Evaluation and Research, and two of his agency colleagues. they emphasize the need for long-term studies when employing CAR-T cell therapy for autoimmune conditions, aligning with standard practices for genetic therapies and CAR-T cell treatments used in oncology. Annals of Internal Medicine
While the paper doesn’t specify a precise timeframe for monitoring autoimmune patients, it draws a parallel to cancer cases, where the FDA mandates patient tracking for up to 15 years after initial treatment. This extended follow-up is crucial for identifying and addressing potential delayed adverse events.
understanding CAR-T Cell Therapy
CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, is a type of immunotherapy that involves genetically modifying a patient’s own immune
Related reading